Skip to main content
OpenTrials
Completed

NCT Number: NCT07796945

Human Neutrophil Lipocalin as an Aid in the Diagnosis of Bacterial Infection in the Emergency Department

The aim of this study is to improve the medical care of patients with infections for which the cause cannot be clearly identified as bacterial or viral. To achieve this, we are investigating a new inflammatory marker in the blood that may help identify severe bacterial infections more quickly. Early detection is important to prevent complications and ensure that patients receive the most appropriate treatment as soon as possible.

This is an observational study. The knowledge gained from this study may help improve the care of patients with infections of unclear origin by supporting faster diagnosis, earlier treatment, improved risk assessment, and better planning of follow-up care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

About this study

This observational study evaluates the diagnostic and prognostic value of Human Neutrophil Lipocalin (HNL) in patients presenting to the Emergency Department (ED) with suspected infection.

Early identification of bacterial infection and sepsis remains a major challenge in emergency care due to the heterogeneity of clinical presentations and the lack of highly accurate diagnostic tools. In particular, distinguishing patients at low risk from those at risk of clinical deterioration is crucial for appropriate treatment decisions, triage, and disposition planning. Delayed recognition of bacterial infection and sepsis is associated with adverse outcomes, especially in patients with atypical presentations.

HNL has emerged as a promising biomarker for differentiating bacterial from viral infections. Previous studies have demonstrated a high diagnostic accuracy of HNL, with reported sensitivity and specificity exceeding 90%, potentially outperforming routinely used biomarkers such as white blood cell count (WBC) and C-reactive protein (CRP). A rapid and reliable biomarker for identifying bacterial infection could support earlier diagnosis, optimize patient management, reduce progression to sepsis, and contribute to more appropriate antibiotic use.

The primary objective of this study is to assess the diagnostic performance of HNL for the detection of bacterial infection in ED patients and to compare its accuracy with routinely used biomarkers, including WBC, CRP, and procalcitonin (PCT).

Secondary objectives include: Comparing the diagnostic performance of HNL measured in serum versus activated Li-heparin whole blood. Evaluating factors that may influence the predictive value of HNL, including age, sex, comorbidities, immunosuppression, and antibiotic treatment. Assessing the prognostic value of HNL for 30-day mortality and comparing its performance with serum lactate, an established predictor of adverse outcomes.

The results of this study may contribute to improved risk stratification and clinical decision-making in patients presenting to the ED with suspected infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults presenting to the Emergency Department with suspected infection
  • Written informed consent provided prior to enrolment
  • Evidence of significant physiological disturbance, defined by abnormal vital signs requiring further medical assessment
  • Symptoms suggestive of a respiratory tract infection (e.g. cough with sputum, worsening cough, or breathing difficulties)
  • Symptoms suggestive of a urinary tract infection (e.g. pain during urination, frequent urination, or urgency)
  • Pain, redness, warmth, or discharge at the site of a vascular catheter or intravenous line
  • Signs of a skin or soft tissue infection, including pain, tenderness, swelling, redness, warmth, or pus formation
  • Nausea, vomiting, abdominal pain, or jaundice suggestive of a possible abdominal infection
  • Headache, neck stiffness, or other symptoms suggestive of a central nervous system infection
  • Abnormal vital signs corresponding to a National Early Warning Score (NEWS) of ≥3 points

Exclusion criteria

  • Known pregnancy at the time of study enrolment
  • Antibiotic treatment that started more than 24 hours before presentation to the Emergency Department
  • Inability or unwillingness to provide written informed consent for study participation

Treatment and study plan

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUROC) for bacterial infection

    Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)

    Diagnostic performance of HNL, WBC, CRP and PCT measured in venous blood samples collected at Emergency Department screening for identifying bacterial infection. Final infection classification (bacterial, viral, other infection, or no infection) will be determined by an independent adjudication committee based on clinical records, laboratory results and microbiological findings.

  2. Sensitivity for bacterial infection

    Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)

    Sensitivity of HNL, WBC, CRP and PCT for identifying bacterial infection using the adjudicated infection diagnosis as the reference standard.

  3. Specificity for sepsis and septic shock

    Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)

    Specificity of HNL, WBC, CRP and PCT for identifying sepsis and septic shock using adjudicated Sepsis-3 diagnoses as the reference standard.

Secondary outcomes

  1. 30-day mortality

    Time frame: 30 days after enrolment

    Death from any cause within 30 days after enrolment, assessed through follow-up contact with the patient's general practitioner, the patient or a relative, or other available sources.

  2. Cause of death

    Time frame: 30 days after enrolment

    Cause of death among participants who die during the 30-day follow-up period.

  3. Hospital re-presentation

    Time frame: 30 days after enrolment

    Re-presentation to hospital occurring within 30 days after enrolment.

  4. Length of hospital stay (LOS)

    Time frame: From hospital admission to discharge, assessed up to 30 days after enrolment

    Length of hospital stay for the index presentation, measured in days from admission to discharge.

  5. Mortality in Emergency Department Sepsis (MEDS) score

    Time frame: Baseline (at Emergency Department presentation)

    MEDS score calculated from baseline clinical variables and patient characteristics obtained at Emergency Department presentation.

  6. Sequential Organ Failure Assessment (SOFA) score

    Time frame: Baseline (at Emergency Department presentation)

    SOFA score calculated from baseline clinical and laboratory variables to assess organ dysfunction.

  7. Quick Sequential Organ Failure Assessment (qSOFA) score

    Time frame: Baseline (at Emergency Department presentation)

    qSOFA score calculated from baseline clinical variables to assess the risk of poor outcomes in patients with suspected infection.

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Collaborators

  • Clinical Trial Unit, University Hospital Basel, Switzerland

Registry information

Official study title

HNL as an Aid in the Diagnosis of Bacterial Infection in the Emergency Department Basel Early Diagnosis of Sepsis (BEDS)

Acronym: BEDS

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Sep 1, 2026
Registry last updated
Sep 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.